Kap-lest-LC Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a potent second-generation antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea associated with allergic reactions. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor, mitigating bronchoconstriction, inflammation, and mucus production commonly observed in asthma and allergic rhinitis. The synergistic action of these two agents provides comprehensive relief from both immediate hypersensitivity symptoms and the late-phase inflammatory response. Kap-lest-LC is indicated for patients requiring combined antihistaminic and leukotriene receptor antagonist therapy, improving symptom control and quality of life. It is generally well tolerated, with adverse effects including headache, fatigue, and gastrointestinal disturbances being infrequent and mild. Dosage should be as prescribed by a healthcare professional, typically one tablet once daily, preferably in the evening. Caution is advised in patients with hepatic or renal impairment, and the medication should be used under medical supervision to monitor for potential drug interactions and contraindications.